vTv Therapeutics to Present Posters at Two Scientific Conferences in September

World News: . []

 Presenting New Clinical Data from Phase 2 Study in Type 1 Diabetes with Liver Selective GKA Program

Pre-Clinical Data in NASH with the NRF2/Bach1 Program 

HIGH POINT, N.C., Sept. 11, 2019 (GLOBE NEWSWIRE) -- (Nasdaq: VTVT), a clinical-stage biopharmaceutical company with leading programs focused on the development of orally administered treatments for diabetes, Alzheimer’s disease and inflammatory disorders, today announced it will be presenting posters with new clinical and pre-clinical data from the company’s Liver Selective GKA Program and its NRF2/Bach1 program at two upcoming European scientific conferences.

Details of the posters are listed below:

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of diabetes, Alzheimer’s disease, and inflammatory disorders. vTv’s development partners are pursuing additional indications in type 2 diabetes, Chronic Obstructive Pulmonary Disease (COPD), and genetic mitochondrial diseases.

or Media:Josh Vlasto212-572-5969

More news and information about vTv Therapeutics Inc.

Published By:

Globe Newswire: 12:30 GMT Wednesday 11th September 2019

Published: .

Search for other references to "therapeutics" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us